ETAS declustering background rate mu indexes GC-independent memory/LLPC niche occupancy and adds incremental 12-month titer prediction beyond peak; the incremental-prediction claim survives a kinetics-controlled partial regression
Earthquake statistics could predict how long your vaccine protection lasts — months before blood tests can tell.
ETAS stochastic declustering background-rate mu as a proxy for early GC-independent LLPC niche occupancy, predicting vaccine antibody-titer durability.
6 bridge concepts›
How this score is calculated ›How this score is calculated ▾
6-Dimension Weighted Scoring
Each hypothesis is scored across 6 dimensions by the Ranker agent, then verified by a 10-point Quality Gate rubric. A +0.5 bonus applies for hypotheses crossing 2+ disciplinary boundaries.
Is the connection unexplored in existing literature?
How concrete and detailed is the proposed mechanism?
How far apart are the connected disciplines?
Can this be verified with existing methods and data?
If true, how much would this change our understanding?
Are claims supported by retrievable published evidence?
Composite = weighted average of all 6 dimensions. Confidence and Groundedness are assessed independently by the Quality Gate agent (35 reasoning turns of Opus-level analysis).
RQuality Gate Rubric
10/17 PASS · 7 CONDITIONAL
| Criterion | Result |
|---|---|
| Novelty | 8 |
| Testability | 7 |
| Groundedness | 7 |
| ABC Structure | PASS |
| Test Protocol | PASS |
| Impact Paradigm | 5 |
| Counter-Evidence | PASS |
| Precision | PASS |
| Per Claim Grounding | PASS |
| Cross Field Distance | 8 |
| Impact Translational | 6 |
| Novelty Web Verified | PASS |
| Mechanism | PASS |
| Confidence | PASS |
| Falsifiable | PASS |
| Mechanistic Specificity | 7 |
| Groundedness Reflects Evidence | PASS |
Claim Verification
Empirical Evidence
How EES is calculated ›How EES is calculated ▾
The Empirical Evidence Score measures independent real-world signals that converge with a hypothesis — not cited by the pipeline, but discovered through separate search.
Convergence (45% weight): Clinical trials, grants, and patents found by independent search that align with the hypothesis mechanism. Strong = direct mechanism match.
Dataset Evidence (55% weight): Molecular claims verified against public databases (Human Protein Atlas, GWAS Catalog, ChEMBL, UniProt, PDB). Confirmed = data matches the claim.
Seismologists have long used a mathematical model called ETAS to separate earthquakes into two categories: the deep, slow 'background rumble' of tectonic stress versus the rapid cascade of aftershocks that follow a big quake. The background rate — called mu — is a kind of baseline hum of seismic activity that ticks along independently of any single event. Meanwhile, immunologists have discovered that when you get vaccinated, your immune system produces two types of long-lived antibody factories: fast, early ones that rush out within days (before your germinal centers, the immune system's training camps, have even spun up) and slower, more refined ones that emerge weeks later from those training camps. The bone marrow has a limited number of 'parking spots' for these factories, and whoever parks first tends to stay longest. This hypothesis proposes something genuinely surprising: that the earthquake background-rate math can be applied to immune cell activity data to measure how many of those early 'parking spots' get claimed in the first week after vaccination. The idea is that people who fill those spots quickly — high mu individuals — end up with more durable antibody protection, not because their cells live longer per se, but because they claimed prime real estate before the competition arrived. The peak antibody level in your blood (what doctors usually measure) wouldn't capture this, because it mostly reflects the later, larger wave of GC-derived cells. Why is this cool? Because it reframes vaccine durability as a real-estate competition problem — and borrows a 20-year-old earthquake statistics tool to measure who wins that competition. If the math holds, you could potentially predict, within the first week or two, whose immunity will last two years and whose will fade in six months.
This is an AI-generated summary. Read the full mechanism below for technical detail.
Why This Matters
If confirmed, this framework could enable early blood-draw predictions of long-term vaccine durability — potentially within the first week post-vaccination, long before traditional titer measurements plateau — which could transform how booster schedules are personalized. Vaccine developers could use mu as a novel optimization target, designing formulations or adjuvants that specifically boost early extrafollicular responses to claim niche space faster. It could also explain persistent mysteries in vaccinology, like why two people with identical peak antibody responses have wildly different protection timelines. The hypothesis is speculative enough to warrant skepticism but grounded enough in real immune biology that testing it with existing longitudinal vaccination datasets and single-cell lineage-tracing tools is entirely feasible and worth doing.
Mechanism
ETAS stochastic declustering (Zhuang-Ogata-Vere-Jones 2002) splits a lineage-resolved immune event catalog into a Poisson background rate mu (homeostatic self-renewal) plus an antigen-triggered fraction. mu is mapped onto the GC-independent memory / long-lived plasma cell (LLPC) niche-occupancy compartment. The argument is niche-competition, not per-cell decay: GC-independent LLPCs seed the limited bone-marrow survival niche early (d3-d7, extrafollicular) before GC-derived LLPCs arrive (d10-d21+); because niches (APRIL/IL-6/BAFF/CXCL12) are not easily displaced once occupied, high-mu individuals occupy more durable niche before the GC arm competes. mu therefore carries a durability signal that response amplitude (peak titer, triggered fraction) does not, even if per-cell decay kinetics of the two LLPC pools are identical.
Supporting Evidence
QG-verified citations: Zhuang, Ogata & Vere-Jones 2002 JASA 97:369-380 (declustering background rate mu); Viant et al. 2021 JEM PMC8193567 (GC-independent memory B cells); Boyman et al. 2009 Eur J Immunol 39:2088-2094 (IL-7/IL-15 homeostatic maintenance); verified extrafollicular timeline (plasmablasts d3-d7 before GC-derived LLPCs d10-d21+); Manz/Radbruch BM-LLPC survival niche (APRIL/IL-6/BAFF/CXCL12).
How to Test
Prospective boost cohort N=30-50 with pre-boost baseline (>=2 timepoints >=4 wk apart) plus dense post-boost sampling (d3/5/7/10/14/28/180/365), BCR VDJ lineage tracing, titers at d28/6mo/12mo. Deconvolve mu and triggered fraction via ETAS declustering (R=50 Monte Carlo, mu IQR<15%). Pre-registered 3-step hierarchical regression of 12-month titer on peak, then +mu, then +triggered fraction and a kinetics-control covariate delta_titer; accept if mu retains partial-r>0.25 (95% CI excludes 0). BM-aspirate LLPC ELISPOT substudy (n>=20) targeting mu vs LLPC count r>0.4; adjuvanted-vs-unadjuvanted enrichment arm. ~$150-250K, 12-24 months.
Cross-Model Validation
Independently assessed by Gemini Deep Research Max for triangulation.
Other hypotheses in this cluster
Can you test this?
This hypothesis needs real scientists to validate or invalidate it. Both outcomes advance science.